Cargando…
The case for intraocular delivery of PPAR agonists in the treatment of diabetic retinopathy
BACKGROUND: Systemic therapeutics targeting the peroxisome proliferator-activated receptors have been found to be beneficial in the treatment of diabetic retinopathy. In this paper, we provide a rationale for the use of these therapeutics as intraocular agents. In addition, we introduce the peroxiso...
Autores principales: | Treacy, Maxwell P, Hurst, Tara P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3532122/ https://www.ncbi.nlm.nih.gov/pubmed/22937835 http://dx.doi.org/10.1186/1471-2415-12-46 |
Ejemplares similares
-
What else can we do to prevent diabetic retinopathy?
por: Simó, Rafael, et al.
Publicado: (2023) -
Diabetic retinopathy in sub-Saharan Africa: meeting the challenges of an emerging epidemic
por: Burgess, Philip I, et al.
Publicado: (2013) -
PPARα Agonist Oral Therapy in Diabetic Retinopathy
por: Tomita, Yohei, et al.
Publicado: (2020) -
Mechanism of worsening diabetic retinopathy with rapid lowering of blood glucose: the synergistic hypothesis
por: Jingi, Ahmadou M., et al.
Publicado: (2017) -
Treatment of the diabetic foot – to amputate or not?
por: Weledji, Elroy P, et al.
Publicado: (2014)